Cancer Immunology – Products

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S.

This literature review explores the latest in 3D immune cell killing assays for cancer immunotherapy research.

Curiox Biosystems announces its collaboration with Dr. Marco Ruella, an assistant professor of medicine at the Perelman School of Medicine, to support efforts in the development of next-generation cancer cell therapies.

Thermo Fisher announced a first of its kind technology to help accelerate the molecule-to-market process by driving efficiency and reducing manufacturing costs.

With six CAR-T drugs currently approved by the FDA and more to follow, Sino Biological has committed to developing reagents and services to support our clients in CAR development, CAR-T preparation and lentivirus packaging, CAR-T cell expansion, and CAR-T quality control.

Sino Biological performs extensive quality control tests to ensure that GMP-grade cytokines meet rigorous quality standards, offering a range of GMP-grade cytokines

During this webinar, we will provide a comprehensive overview of several cytokine therapy approaches, development, and clinical application. We will further discuss how Sino Biological can assist in cancer immunotherapy research.

Sino Biological has launched a comprehensive collection of high-quality bioreagents to support the study and application of cytokines.

Cytiva has launched the NanoAssemblr commercial formulation system, purpose-built for clinical and commercial manufacturing of lipid nanoparticle medicines.